News | Proton Therapy | September 15, 2015

Minnesota facility first to install system with Discrete Spot Scanning capability; Arizona campus to follow suit

Hitachi, Probeat-V, proton beam therapy, Mayo Clinic, Rochester, Minnesota

Image courtesy of Hitachi Ltd.


September 15, 2015 — Hitachi Ltd. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for commercial supply of the new Probeat-V system designed and developed for Mayo Clinic in Rochester, Minnesota. Treatments began in late June and the first patient treatment was completed in August 2015.

The Probeat-V is a state-of-the-art proton beam therapy system used to deliver Hitachi’s Discrete Spot Scanning capability to each treatment room. The 190-degree half gantries provide efficient yet spacious treatment room environments; patients no longer need to be positioned inside a 360-degree gantry, as all treatment angles are achieved by a 6-degree of freedom (DOF) couch. A 30 percent smaller treatment spot size, achieved through refinements in nozzle design, enables the system to achieve highly precise treatments. In addition, installation and commissioning activities are already underway at a second Mayo facility in Phoenix, Arizona, with treatments scheduled to start in the spring of 2016.

Mayo Clinic treats more than 1.3 million patients annually from all 50 states and 143 countries. Mayo Clinic has maintained its position as one of the top hospitals in U.S. News & World Report rankings for more than 20 years.

The Probeat-V system also offers:

  • Beam matching (within 5 percent) technology allowing patients to be treated in any room at any time;
  • Integrated setup rooms to increase patient throughput. Although patients’ visits may often take between 15 to 30 minutes, the time required for irradiation is usually only a few minutes. At Mayo Clinic, setup rooms allow patients to be stabilized and pre-positioned offline, optimizing treatment room utilization and shortening patients’ visits; and
  • An improved user interface, co-developed with Mayo Clinic.

For more information: www.hitachimed.com


Related Content

News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Subscribe Now